Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.
Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
Explore recursive SNARKs and proof composition in blockchain, boosting scalability, efficiency, and secure zero-knowledge verification ...
Online shopping is currently facing its most profound transformation since mobile commerce. On January 11, 2026, at the National Retail Federation conference, Google CEO Sundar Pichai announced the ...
A team of researchers has found a way to steer the output of large language models by manipulating specific concepts inside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results